Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients.

摘要: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the currently recommended treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). Acquired resistance inevitably develops, with T790M mutation comprising approximately 55% of mechanisms following first- or second-generation EGFR-TKI therapy (e.g. gefitinib, erlotinib, afatinib, and dacomitinib). Patients without a heterogeneous group whom platinum-based chemotherapy is as second-line treatment. In addition to secondary mutations in T790M), known can be classified into three categories: bypass pathways, downstream signaling histologic transformations. Given evolving knowledge convenience diagnosing acquired by next-generation sequencing liquid biopsy, exploratory studies targeting these incorporating immunotherapy paradigm have become mainstream future development. This review focuses on other than that develop after therapy. Exploratory treatments well combination ongoing clinical trials reviewed here. We also highlight recent development biopsy this field.